{"name":"Neurovance","permalink":"neurovance","crunchbase_url":"http://www.crunchbase.com/company/neurovance","homepage_url":"http://www.euthymics.com","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":"biotech","number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":"","alias_list":"","email_address":"","phone_number":"617-758-0300","description":"","created_at":"Fri Oct 19 05:35:25 UTC 2012","updated_at":"Mon Nov 26 03:14:16 UTC 2012","overview":"<p>Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurovance also holds a substantial portfolio of research stage reuptake inhibitors.</p>\n\n<p>Euthymics and Neurovance are private corporations with common headquarters in Cambridge, Massachusetts.</p>","image":null,"products":[],"relationships":[],"competitions":[],"providerships":[],"total_money_raised":"$7M","funding_rounds":[{"round_code":"a","source_url":"http://finance.yahoo.com/news/neurovance-closes-7m-series-a1-113200571.html","source_description":"Neurovance Closes $7M Series A1 Round for Development of EB-1020 for ADHD; Reports Phase 1 Clinical Trial Results","raised_amount":7000000,"raised_currency_code":"USD","funded_year":2012,"funded_month":10,"funded_day":18,"investments":[{"company":null,"financial_org":{"name":"Novartis Venture Fund","permalink":"novartis-venture-fund","image":{"available_sizes":[[[150,13],"assets/images/resized/0005/9083/59083v1-max-150x150.jpg"],[[212,19],"assets/images/resized/0005/9083/59083v1-max-250x250.jpg"],[[212,19],"assets/images/resized/0005/9083/59083v1-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"Venture Investors","permalink":"venture-investors","image":{"available_sizes":[[[150,40],"assets/images/resized/0006/2067/62067v1-max-150x150.jpg"],[[217,58],"assets/images/resized/0006/2067/62067v1-max-250x250.jpg"],[[217,58],"assets/images/resized/0006/2067/62067v1-max-450x450.jpg"]],"attribution":null}},"person":null},{"company":null,"financial_org":{"name":"H&Q Healthcare Investors","permalink":"h-q-healthcare-investors","image":null},"person":null},{"company":null,"financial_org":{"name":"H&Q Life Sciences Investors","permalink":"h-q-life-sciences-investors","image":null},"person":null},{"company":null,"financial_org":{"name":"GBS Ventures","permalink":"gbs-ventures","image":{"available_sizes":[[[100,74],"assets/images/resized/0004/8580/48580v1-max-150x150.png"],[[100,74],"assets/images/resized/0004/8580/48580v1-max-250x250.png"],[[100,74],"assets/images/resized/0004/8580/48580v1-max-450x450.png"]],"attribution":null}},"person":null}]}],"investments":[],"acquisition":null,"acquisitions":[],"offices":[],"milestones":[],"ipo":null,"video_embeds":[],"screenshots":[],"external_links":[]}